Three major uncertainties in the antibody therapy of cancer

Haematologica

Volumn 99, Issue 10, 2014, Pages 1538-1546

  Stevenson, George T ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIIDIOTYPIC ANTIBODY; CD20 ANTIBODY; FC RECEPTOR IIB; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M; OBINUTUZUMAB; RITUXIMAB; ANTIGEN; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY THERAPY; ANTIGENIC MODULATION; CANCER IMMUNOTHERAPY; CELL MEDIATED CYTOTOXICITY; CHRONIC LYMPHATIC LEUKEMIA; COMPLEMENT DEPENDENT CYTOTOXICITY; DRUG EFFICACY; HUMAN; INTERNALIZATION; MACROPHAGE; MULTICENTER STUDY (TOPIC); NATURAL KILLER CELL; NEUTROPHIL; NONHUMAN; PHAGOCYTOSIS; REVIEW; TUMOR CELL; X RAY CRYSTALLOGRAPHY; ANIMAL; CYTOTOXICITY; IMMUNOLOGY; IMMUNOMODULATION; NEOPLASMS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS; ANTINEOPLASTIC AGENTS; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; IMMUNOMODULATION; NEOPLASMS;

EID: 84907518808     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2013.084640     Document Type: Review

References (100)

1. Maloney DG, Grillo-López AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA, et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood. 1997;90(6):2188-95.
2. Maloney DG. Anti-CD20 antibody therapy for B-cell lymphomas. N Engl J Med. 2012; 366(21):2008-16.
3. Tan D, Horning SJ, Hoppe RT, Levy R, Rosenberg SA, Sigal BM, et al. Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience. Blood. 2013;122(6):961-7.
4. Ghielmini M. Single agent rituximab is a valid option for first-line treatment in follicular lymphoma. Ann Oncol. 2011;22(Suppl 4):iv81.
5. Martinelli G, Schmitz SF, Utiger U, Cerny T, Hess U, Bassi S, et al. Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98. J Clin Oncol. 2010;28(29):4480-4.
6. Barré-Sinoussi F, Montagnier L, Lidereau R, Sisman J, Wood J, Chermann JC. Enhancement of retrovirus production by anti-interferon serum. Ann Microbiol (Paris). 1979;130B(3):349-62.
7. Young GR, Eksmond U, Salcedo R, Alexopoulou L, Stoye JP, Kassiotis G. Resurrection of endogenous retroviruses in antibody-deficient mice. Nature. 2012;491 (7426):774-8.
8. Crick FH. In What Mad Pursuit: A Personal View of Scientific Discovery. Basic Books. New York, New York. 1988; p. 146.
9. Stevenson GT, Stevenson FK. Antibody to a molecularly-defined antigen confined to a tumour cell surface. Nature. 1975;254 (5502):714-6.
10. Hough DW, Eady RP, Hamblin TJ, Stevenson FK, Stevenson GT. Anti-idiotype sera raised against surface immunoglobulin of human neoplastic lymphocytes. J Exp Med. 1976;144(4):960-9.
11. Stevenson FK, Hamblin TJ, Stevenson GT, Tutt AL. Extracellular idiotypic immunoglobulin arising from human leukemic B lymphocytes. J Exp Med. 1980; 152(6):1484-96.
12. Miller RA, Maloney DG, Warnke RA, Levy R. Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. N Engl J Med. 1982;306(9):517-22.
13. Meeker TC, Lowder J, Maloney DG, Miller RA, Thielemans K, Warnke R, et al. A clinical trial of anti-idiotype therapy for B cell malignancy. Blood. 1985;65(6):1349-63.
14. Davis TA, Maloney DG, Czerwinski DK, Lilies TM, Levy R. Anti-idiotype antibodies can induce long-term complete remissions in non-Hodgkin's lymphoma without eradicating the malignant clone. Blood. 1998; 92(4):1184-90.
15. Stevenson FK, Stevenson GT. Follicular lymphoma and the immune system: from pathogenesis to antibody therapy. Blood. 2012;119(16):3659-67.
16. Riley JK, Sliwkowski MX. CD20: a gene in search of a function. Semin Oncol. 2000;27(6, Suppl 12):17-24.
17. Beers SA, Chan CH, James S, French RR, Attfield KE, Brennan CM, et al. Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation. Blood. 2008;112(10):4170-7.
18. Klein C, Lammens A, Schäfer W, Georges G, Schwaiger M, Mössner E, et al. Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties. Mabs. 2013;5(1):22-33.
19. Davis TA, Czerwinski DK, Levy R. Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression. Clin Cancer Res. 1999;5(3):611-5.
20. Kennedy GA, Tey SK, Cobcroft R, Marlton P, Cull G, Grimmett K, et al. Incidence and nature of CD20-negative relapses following rituximab therapy in aggressive B-cell non-Hodgkin's lymphoma: a retrospective review. Br J Haematol. 2002;119(2):412-6.
21. Marsden VS, Strasser A. Control of apoptosis in the immune system: Bcl-2, BH3-only proteins and more. Annu Rev Immunol. 2003;21:71-105.
22. Hubert P, Heitzmann A, Viel S, Nicolas A, Sastre-Garau X, Oppezzo P, et al. Antibodydependent cell cytotoxicity synapses form in mice during tumor-specific antibody immunotherapy. Cancer Res. 2011;71(15): 5134-43.
23. Albanesi M, Mancardi DA, Jönsson F, Iannascoli B, Fiette L, Di Santo JP, et al. Neutrophils mediate antibody-induced antitumor effects in mice. Blood. 2013;122(18): 3160-4.
24. Wang SY, Racila E, Taylor RP, Weiner GJ. NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximabcoated target cells is inhibited by the C3b component of complement. Blood. 2008; 111(3):1456-63.
25. Stackpole CW, Jacobson JB, Galuska S. Antigenic modulation in vitro. II. Modulation of thymus leukemia (TL) antigenicity requires complement component C3. J Immunol. 1978;120(1):188-97.
26. Zhang S, Wu CC, Fecteau JF, Cui B, Chen L, Zhang L, et al. Targeting chronic lymphocytic leukemia cells with a humanized monoclonal antibody specific for CD44. Proc Natl Acad Sci USA. 2013;110(15):6127-32.
27. Shan D, Ledbetter JA, Press OW. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood. 1998;91(5):1644-52.
28. Ivanov A, Beers SA, Walshe CA, Honeychurch J, Alduaij W, Cox KL. Monoclonal antibodies directed to CD20 and HLA-DR can elicit homotypic adhesion followed by lysosome-mediated cell death in human lymphoma and leukemia cells. J Clin Invest. 2009;119(8):2143-59.
29. Scarlatti F, Granata R, Meijer AJ, Codogno P. Does autophagy have a licence to kill mammalian cells? Cell Death Differ. 2009;16(1):12-20.
30. Bucur O, Stancu AL, Khosravi-Far R, Almasan A. Analysis of apoptosis methods recently used in Cancer Research and Cell Death & Disease publications. Cell Death Dis. 2012;3:e263.
31. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med. 2000;6(4):443-6.
32. Clynes R, Takechi Y, Moroi Y, Houghton A, Ravetch JV. Fc receptors are required in passive and active immunity to melanoma. Proc Natl Acad Sci USA. 1998;95(2):652-6.
33. Nimmerjahn F, Bruhns P, Horiuchi K, Ravetch JV. FcγRIV: a novel FcR with distinct IgG subclass specificity. Immunity. 2005; 23(1):41-51.
34. Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene. Blood. 2002;99(3):754-58.
35. Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol. 2003;21(21):3940-7.
36. Persky DO, Dornan D, Goldman BH, Braziel RM, Fisher RI, LeBlanc M, et al. Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemoptherapy but not chemotherapy alone. Haematologica. 2012; 97(6):937-42.
37. Farag SS, Flinn IW, Modali R, Lehman TA, Young D, Byrd JC. FcγRIIIa and FcγRIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia. Blood. 2004;103(4):1472-4.
38. Dornan D, Spleiss O, Yeh R-F, Duchateau-Nguyen G, Dufour A, Zhi J, et al. Effect of FCGR2A and FCGR3A variants on CLL outcome. Blood. 2010;116(20):4212-22.
39. Desjarlais JR, Lazar GA, Zhukovsky EA, Chu SY. Optimizing engagement of the immune system by anti-tumor antibodies: an engineer's perspective. Drug Discov Today. 2007;12(21-22):898-910.
40. Dutertre CA, Bonnin-Gélizé E, Pulford K, Bourel D, Fridman WH, Teillaud JL. A novel subset of NK cells expressing high levels of inhibitory FcγRIIB modulating antibodydependent function. J Leukoc Biol. 2008;84 (6):1511-20.
41. Uchida JC, Hamaguchi Y, Oliver JA, Ravetch JV, Poe JC, Haas KM, Tedder TF. The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J Exp Med. 2004;199 (12):1659-69.
42. Hamaguchi Y, Xiu Y, Komura K, Nimmerjahn F, Tedder TF. Antibody isotypespecific engagement of Fcγ receptors regulates B lymphocyte depletion during CD20 immunotherapy. J Exp Med. 2006;203(3): 743-53.
43. Van Ravenswaay Claasen HH, Kluin PM, Fleuren GJ. Tumor infiltrating cells in human cancer. On the possible role of CD16+ macrophages in antitumor cytotoxicity. Lab Invest. 1992;67(2):166-74.
44. Golay J, Da Roit F, Bologna L, Ferrara C, Leusen JH, Rambalda A, et al. Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab. Blood. 2013;122 (20):3482-91.
45. Locati M, Mantovani A, Sica A. Macrophage activation and polarization as an adaptive component of innate immunity. Adv Immunol. 2013;120:163-84.
46. Griffin FM, Griffin JA, Leider JE, Silverstein SC. Studies on the mechanism of phagocytosis. I. Requirements for circumferential attachment of particle-bound ligands to specific receptors on the macrophage plasma membrane. J Exp Med. 1975;142(5):1263-82.
47. Griffin FM, Griffin JA, Silverstein SC. Studies on the mechanism of phagocytosis. II. The interaction of macrophages with anti-immunoglobulin IgG-coated bone-marrow derived lymphocytes. J Exp Med. 1976;144(3):788-809.
48. Baba T, Iwasaki S, Maruoka T, Suzuki A, Tomaru U, Ikeda H. Rat CD4+CD8+ macrophages kill tumor cells through an NKG2D-and granzyme/perforin-dependent mechanism. J Immunol. 2008;180(5):2999-3006.
49. Lefebvre ML, Krause SW, Salcedo M, Nardin A. Ex vivo-activated human macrophages kill chronic lymphocytic leukemia cells in the presence of rituximab: mechanism of antibody-dependent cellular cytotoxicity and impact of human serum. J Immunother. 2006;29(4):388-97.
50. Sanderson CJ, Thomas JA. A comparison of the cytotoxic activity of eosinophils and other cells by 51chromium release and time lapse microcinematography. Immunology. 1978;34(4):771-80.
51. Joli E, Hudrisier D. What is trogocytosis and what is its purpose? Nat Immunol. 2003; 4(9):815.
52. Rudnicka D, Oszmiana A, Finch DK, Strickland I, Schofield DJ, Lowe DC, et al. Rituximab causes a polarization of B cells that augments its therapeutic function in NK-cellmediated antibody-dependent cellular cytotoxicity. Blood. 2013;121(23):4694-702.
53. Vilches C, Parham P. KIR: rapidly evolving receptors of innate and adaptive immunity. Ann Rev Immunol. 2002;20:217-51.
54. Law SK, Reid KB. Control of complement. In Complement, 2nd ed. IRL Press, Oxford, 1995; pp 22-27.
55. Hersey P. New look at antiserum therapy of leukaemia. Nature New Biol. 1973;244 (131):22-4.
56. Lanier LL, Babcock GF, Raybourne RB, Arnold LW, Warner NL, Haughton G. Mechanism of B cell lymphoma therapy with passive xenogeneic anti-idiotype serum. J Immunol. 1980;125(4):1730-6.
57. Stevenson GT, Glennie MJ. Surface immunoglobulin of B-lymphocytic tumours as a therapeutic target. Cancer Surv. 1985;4(1):214-44.
58. Bernstein ID, Tam MR, Nowinski RC. Mouse leukemia: therapy with monoclonal antibodies against a thymus differentiation antigen. Science. 1980;207(4426):1980.
59. Bologna L, Gotti E, Manganini M, Rambaldi A, Intermesoli T, Introna M, et al. Mechanism of action of type II, glycoengineered, anti-CD20 monoclonal antibody GA101 in B-chronic lymphocytic leukemia whole blood assays in comparison with rituximab and alemtuzumab. J Immunol. 2011;186(6):3762-9.
60. Weng WK, Levy R. Expression of complement inhibitors CD46, CD55 and CD59 on tumor cells does not predict the clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma. Blood. 2001; 98(5):1352-7.
61. Shushakova N, Skokowa J, Schulman J, Baumann U, Zwirner J, Schmidt RE, et al. C5a anaphylatoxin is a major regulator of activating versus inhibitory FcγRs in immune complex-induced lung disease. J Clin Invest. 2002;110(12):1823-30.
62. Sondermann P, Huber R, Oosthuizen V, Jacob U. The 3.2-Å crystal structure of the human IgG1 Fc fragment BFcγRIII complex. Nature. 2000;406(6793):267-73.
63. Lazar GA, Dang W, Karki S, Vafa O, Peng JS, Hyun L, et al. Engineered antibody Fc variants with enhanced effector function. Proc Natl Acad Sci USA. 2006;103(11):4005-10.
64. Stavenhagen JB, Gorlatov S, Tuaillon N, Rankin CT, Li H, Burke S, et al. Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcγ receptors. Cancer Res. 2007;67(18):8882-90.
65. Shields RL, Lai J, Keck R, O' Connell LY, Hong K, Meng YG, et al. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human FcγRIII and antibody-dependent cellular toxicity. J Biol Chem. 2002;277(30):26733-40.
66. Leong WS, Thomas KA, Chan CH, Stevenson GT. A standardized conversion of IgG antibody to bispecific form with inversely altered affinities for Fcγ-receptors II and III. Mol Immunol. 2011;48(5):760-8.
67. Ratner M. Genentech's glyco-engineered antibody to succeed rituxan. Nat Biotechnol. 2014;32(1):6-7.
68. Old LJ, Boyse EA. Antigenic properties of experimental leukemias. I. Serological studies in vitro with spontaneous and radiationinduced leukemias. J Natl Cancer Inst. 1963;31:977-95.
69. Stackpole CW, Jacobson JB, Lardis MP. Antigenic modulation in vitro. I. Fate of thymus-leukemia (TL) antigen-antibody complexes following modulation of TL antigenicity from the surfaces of mouse leukemia cells and thymocytes. J Exp Med. 1974;140(4):939-53.
70. Schroff RW, Farrell MM, Klein RA, Stevenson HC, Warner NL. Induction and enhancement by monocytes of antibodyinduced modulation of a variety of human lymphoid cell surface antigens. Blood. 1985; 66(3):620-6.
71. Schreiner GF, Unanue ER. Membrane and cytoplasmic changes in B lymphocytes induced by ligand-surface immunoglobulin interaction. Adv Immunol. 1976;24:37-165.
72. Gordon J, Stevenson GT. Antigenic modulation of lymphocytic surface immunoglobulin yielding resistance to complement-mediated lysis. II. Relation to redistribution of the antigen. Immunology. 1981;42(1):13-7.
73. Glennie M, Stevenson FK, Stevenson GT, Virji M. Cross-linking of surface immunoglobulin inhibits its production via a cyclic nucleotide mechanism. Nature. 1979; 281(5729):305-7.
74. Elliott TJ, Glennie MJ, McBride HM, Stevenson GT. Analysis of the interaction of antibodies with immunoglobulin idiotypes on neoplastic B lymphocytes: implications for immunotherapy. J Immunol. 1987;138 (3):981-8.
75. Lane AC, Foroozan S, Glennie MJ, Kowalski-Saunders P, Stevenson GT. Enhanced modulation of antibodies coating guinea pig leukemic cells in vitro and in vivo. The role of FcγR expressing cells. J Immunol. 1991;146(7):2461-8.
76. Press OW, Howell-Clark J, Anderson S, Bernstein I. Retention of B-cell-specific monoclonal antibodies by human lymphoma cells. Blood. 1994;83(5):1390-7.
77. Press OW, Farr AG, Borroz I, Anderson SK, Martin PJ. Endocytosis and degradation of monoclonal antibodies targeting B-cell malignancies. Cancer Res. 1989;49(9):4906-12.
78. Glennie MJ, Stevenson GT. Univalent antibodies kill tumor cells in vitro and in vivo. Nature. 1982;295(5851):712-4.
79. Maloney DG, Liles TM, Czerwinski DK, Waldichuk C, Rosenberg J, Grillo-Lopez A, et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody in patients with recurrent B-cell lymphoma. Blood. 1994;84(8) 2457-66.
80. Jilani I, O' Brien S, Manshuri T, Thomas DA, Thomazy VA, Imam M, et al. Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemia. Blood. 2003;102(10):3514-20.
81. Beers SA, French RR, Claude Chan HT, Lim SH, Jarrett TC, Vidal RM, et al. Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection. Blood. 2010;115(25):5191-201.
82. Vervoordeldonk SF, Merle PA, van Leeuwen EF, van der Schoot CE, von dem Borne AE, Slaper-Cortenbach IC. Fcγ receptor II (CD32) on malignant B cells influences modulation induced by anti-CD19 monoclonal antibody. Blood. 1994;83(6):1632-9.
83. Zhang CY, Booth JW. Divergent intracellular sorting of FcγRIIA and FcγRIIB2. J Biol Chem. 2010;285(44):34250-8.
84. Mousavi SA, Sporstøl M, Fladeby C, Kjeken R, Barois N, Berg T. Receptor-mediated endocytosis of immune complexes in rat liver sinusoidal endothelial cells is mediated by FcγRIIB2. Hepatology. 2007;46(3):871-84.
85. Vaughan AT, Iriyama C, Beers SA, Chan CH, Lim SH, Williams EL, et al. Inhibitory FcγRIIb (CD32b) becomes activated by therapeutic mAb in both cis and trans and drives internalization according to antibody specificity. Blood. 2014;123(5):669-77.
86. Callanan MB, le Baccon P, Mossuz P, Duley S, Bastard C, Hamoudi R, et al. The IgG Fc receptor, FcγRIIb, is a target for deregulation by chromosomal translocation in malignant lymphoma. Proc Natl Acad Sci USA. 2000; 97(1):309-14.
87. Chen W, Palanisamy N, Schmidt H, Teruya-Feldstein J, Jhanwar SC, Zelenetz AD, et al. Deregulation of FCGR2B expression by 1q21 rearrangements in follicular lymphomas. Oncogene. 2001;20(52):7686-93.
88. Kennedy AD, Beum PV, Solga MD, Di Lillo DJ, Lindorfer MA, Hess CE, et al. Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia. J Immunol. 2004;172(5): 3280-8.
89. Beum PV, Kennedy AD, Williams ME, Lindorfer MA, Taylor RP. The shaving reaction: rituximab/CD20 complexes are removed from mantle cell lymphoma and chronic lymphocytic leukemia cells by THP-1 monocytes. J Immunol. 2006;176(4):2600-9.
90. Rossi EA, Goldenberg DM, Michel R, Rossi DL, Wallace DJ, Chang CH. Trogocytosis of multiple B-cell surface markers by CD22 targeting with epratuzumab. Blood. 2013; 122(17):3020-9.
91. Taylor RP. Gnawing at Metchnikoff's paradigm. Blood. 2013;122(17):2922-4.
92. Berinstein NL, Grillo-López AJ, White CA, Bence-Bruckler I, Maloney D, Czuczman M, et al. Association of serum rituximab (IDECC2B8) concentration and anti-tumor response in the treatment of recurrent lowgrade or follicular non-Hodgkin's lymphoma. Ann Oncol. 1998;9(9):995-1001.
93. Teeling JL, Jansen-Hendriks T, Kuijpers TW, de Haas M, van de Winkel JG, Hack CE, et al. Therapeutic efficacy of intravenous immunoglobulin preparations depends on the immunoglobulin G dimers: studies in immune thrombocytopenia. Blood. 2001; 98(4):1095-9.
94. Clynes R. Protective mechanisms of IVIG. Curr Opin Immunol. 2007;19(6):646-51.
95. Yu X, Vasilijevic S, Mitchell DA, Crispin M, Scanlan CN. Dissecting the molecular mechanism of IVIg therapy: the interaction between serum IgG and DC-SIGN is independent of antibody glycoform or Fc domain. J Mol Biol. 2013;425(8):1253-8.
96. Imbach P, Morell A. Idiopathic thrombocytopenic purpura (ITP): immunomodulation by intravenous immunoglobulin (IVIg). Int Rev Immunol. 1989;5:181-8
97. Samuelsson A, Towers TL, Ravetch JV. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science. 2001;291(5503):484-6.
98. Song S, Crow AR, Siragam V, Freedman J, Lazarus AH. Intravenous antibodies that mimic the action of anti-D in the amelioration of murine ITP act by a mechanism distinct from that of IVIg. Blood. 2005;105 (4):1546-8.
99. Siragam V, Crow AR, Brinc D, Song S, Freedman J, Lazarus AH. Intravenous immunoglobulin ameliorates ITP via activating Fcγ receptors on dendritic cells. Nat Med. 2006;12(6):688-92.
100. Park-Min KH, Serbina NV, Yang W, Ma X, Krystal G, Neel BG, et al. FcγRIII-dependent inhibition of interferon-γ responses mediates suppressive effects of intravenous immune globulin. Immunity. 2007;26(1):67-78.